A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)
Completed
Boehringer Ingelheim
Phase 4
2002-12-01
The primary objective of this study was test non-inferiority of telmisartan 80 mg +
hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in
reducing ambulatory systolic blood pressure (SBP) in the last 6 hours of the 24-hour dosing
interval (determined by ambulatory blood pressure monitoring: ABPM) in elderly patients with
predominantly systolic hypertension.
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
Completed
Boehringer Ingelheim
Phase 4
2005-10-01
The objective of the study is to compare PPAR activities (increase of adiponectin level)
between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with
metabolic syndrome. Moreover, this study will compare serum level of inflammatory markers of
the metabolic syndrome after 6 weeks of treatment.
An ancillary study performed in one center will assess adipocyte differentiation (PPAR gamma
stimulation) in 30 subjects (15 per arm).
Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine
Completed
Tokyo University
Phase 4
2007-07-01
The purpose of this study is to compare depressor effect and safety between combination
therapy with telmisartan plus low-dose hydrochlorothiazide and amlodipine in hypertensive
patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
